Phibro Animal Health (NASDAQ:PAHC) CEO Sells $235,429.36 in Stock

December 16, 2025 by InsiderTrades.com

Key Points

CEO Jack Bendheim sold 5,752 shares on Dec. 11 at $40.93 for $235,429.36, reducing his position by 12.8% to 39,200 shares (worth ≈$1.60M).
The Dec. 11 sale is part of a string of large insider dispositions in Nov–Dec (e.g., 38,303 shares sold on Nov. 10 for ≈$1.73M), indicating substantial insider selling in recent weeks.
Company fundamentals: Phibro beat quarterly EPS ($0.73 vs. $0.58) and revenue estimates, set FY2026 guidance of $2.64–$2.81 EPS, and declared a $0.12 quarterly dividend (≈1.2% yield).

Phibro Animal Health Corporation (NASDAQ:PAHC - Get Free Report) CEO Jack Bendheim sold 5,752 shares of the stock in a transaction on Thursday, December 11th. The shares were sold at an average price of $40.93, for a total value of $235,429.36. Following the sale, the chief executive officer owned 39,200 shares in the company, valued at approximately $1,604,456. This trade represents a 12.80% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link.

Jack Bendheim also recently made the following trade(s):

On Tuesday, December 9th, Jack Bendheim sold 1,288 shares of Phibro Animal Health stock. The shares were sold at an average price of $40.19, for a total value of $51,764.72.
On Monday, December 8th, Jack Bendheim sold 3,520 shares of Phibro Animal Health stock. The stock was sold at an average price of $40.06, for a total value of $141,011.20.
On Wednesday, December 3rd, Jack Bendheim sold 3,520 shares of Phibro Animal Health stock. The shares were sold at an average price of $40.77, for a total transaction of $143,510.40.
On Tuesday, November 25th, Jack Bendheim sold 7,040 shares of Phibro Animal Health stock. The stock was sold at an average price of $43.93, for a total transaction of $309,267.20.
On Wednesday, November 26th, Jack Bendheim sold 5,280 shares of Phibro Animal Health stock. The stock was sold at an average price of $44.02, for a total transaction of $232,425.60.
On Monday, November 17th, Jack Bendheim sold 5,280 shares of Phibro Animal Health stock. The shares were sold at an average price of $44.56, for a total transaction of $235,276.80.
On Thursday, November 13th, Jack Bendheim sold 8,801 shares of Phibro Animal Health stock. The shares were sold at an average price of $44.47, for a total transaction of $391,380.47.
On Wednesday, November 12th, Jack Bendheim sold 21,536 shares of Phibro Animal Health stock. The stock was sold at an average price of $45.23, for a total transaction of $974,073.28.
On Monday, November 10th, Jack Bendheim sold 38,303 shares of Phibro Animal Health stock. The stock was sold at an average price of $45.29, for a total transaction of $1,734,742.87.
On Friday, November 7th, Jack Bendheim sold 3,520 shares of Phibro Animal Health stock. The shares were sold at an average price of $42.86, for a total value of $150,867.20.

Phibro Animal Health Price Performance

PAHC stock opened at $40.67 on Tuesday. The stock has a market capitalization of $1.65 billion, a price-to-earnings ratio of 24.50, a price-to-earnings-growth ratio of 1.14 and a beta of 0.77. The company has a quick ratio of 1.35, a current ratio of 3.09 and a debt-to-equity ratio of 2.32. Phibro Animal Health Corporation has a 52-week low of $16.16 and a 52-week high of $46.42. The stock's fifty day simple moving average is $41.29 and its 200-day simple moving average is $34.77.

Phibro Animal Health (NASDAQ:PAHC - Get Free Report) last released its earnings results on Wednesday, November 5th. The company reported $0.73 EPS for the quarter, beating the consensus estimate of $0.58 by $0.15. Phibro Animal Health had a return on equity of 36.26% and a net margin of 4.85%.The firm had revenue of $363.89 million during the quarter, compared to analyst estimates of $345.44 million. Phibro Animal Health has set its FY 2026 guidance at 2.640-2.810 EPS. Equities research analysts expect that Phibro Animal Health Corporation will post 1.95 EPS for the current year.

Phibro Animal Health Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Wednesday, December 17th. Investors of record on Wednesday, November 26th will be given a dividend of $0.12 per share. The ex-dividend date of this dividend is Wednesday, November 26th. This represents a $0.48 annualized dividend and a yield of 1.2%. Phibro Animal Health's dividend payout ratio is 28.92%.

Analyst Ratings Changes

A number of equities analysts have weighed in on PAHC shares. Weiss Ratings reiterated a "buy (b-)" rating on shares of Phibro Animal Health in a report on Monday, December 8th. Zacks Research upgraded Phibro Animal Health from a "hold" rating to a "strong-buy" rating in a report on Tuesday, December 9th. Bank of America boosted their price target on Phibro Animal Health from $19.00 to $27.00 and gave the company an "underperform" rating in a research report on Friday, August 29th. Morgan Stanley set a $34.00 price objective on Phibro Animal Health in a report on Thursday, August 28th. Finally, JPMorgan Chase & Co. boosted their target price on Phibro Animal Health from $45.00 to $50.00 and gave the stock an "overweight" rating in a report on Friday, November 7th. One equities research analyst has rated the stock with a Strong Buy rating, two have assigned a Buy rating, three have assigned a Hold rating and two have given a Sell rating to the company's stock. According to MarketBeat, Phibro Animal Health presently has an average rating of "Hold" and a consensus price target of $31.40.

Get Our Latest Stock Report on PAHC

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in the company. LPL Financial LLC raised its position in shares of Phibro Animal Health by 46.8% during the first quarter. LPL Financial LLC now owns 128,335 shares of the company's stock worth $2,741,000 after purchasing an additional 40,889 shares during the period. Kings Path Partners LLC increased its stake in Phibro Animal Health by 87.3% during the 2nd quarter. Kings Path Partners LLC now owns 20,600 shares of the company's stock valued at $526,000 after purchasing an additional 9,600 shares in the last quarter. Voya Investment Management LLC raised its holdings in Phibro Animal Health by 44.3% during the first quarter. Voya Investment Management LLC now owns 31,894 shares of the company's stock worth $681,000 after buying an additional 9,796 shares during the last quarter. Trexquant Investment LP bought a new stake in Phibro Animal Health during the 1st quarter worth approximately $385,000. Finally, Bailard Inc. purchased a new position in shares of Phibro Animal Health in the 2nd quarter worth about $259,000. 99.34% of the stock is currently owned by hedge funds and other institutional investors.

Phibro Animal Health Company Profile

(Get Free Report)

Phibro Animal Health Corporation operates as an animal health and mineral nutrition company in the United States, Israel, Brazil, Ireland, and internationally. It operates through three segments: Animal Health, Mineral Nutrition, and Performance Products. The company develops, manufactures, and markets various products for food and companion animals including poultry, swine, beef and dairy cattle, aquaculture, and dogs.